Clinical trial · Observational
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)
NCT03283956CI-TRIAL-00029563SERENADE-TunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemoembolization, Therapeutic | — | UNRESOLVED | — |
| Hepatocellular Carcinoma Non-resectable | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient records | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient records
- description
- Medical records of all patients who underwent DC bead TACE.
- interventionNames
- Device: Patient records
Primary outcomes (1)
- measure
- Safety of the DC bead TACE
- timeFrame
- One year.
- description
- Safety of the DC bead TACE is evaluated based on the incidence of Grade 3 and Grade 4 toxicities up to 8 weeks following the procedure according to National Cancer Institute's Common Terminology Criteria for adverse events (CTCAE Version 4.03).
Secondary outcomes (1)
- measure
- Tumor response
- timeFrame
- One year.
- description
- Tumor response is assessed on triphase CT or contrast-enhanced MR study according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of HCC, according to the AASLD diagnosis criteria for HCC. * Patient received DC bead TACE. Exclusion Criteria: * Patients with current any other cancer except non-melanomatous skin cancer. * Infiltrative HCC * Patients received ≥2 consecutive sessions of TACE (≥2 TACE at the same admission, no matter it is cTACE or DC bead TACE) * Patients received DC bead TACE and simultaneously received other therapy, such as radiotherapy, sorafenib etc. * Presence of collateral vessel pathways potentially endangering normal territories during embolization. * Presence of arteries supplying the lesion not large enough to accept DC Bead® microspheres.
References
Publications (0)
Data not yet available
No reference posted for this study.